After much anticipation, new dyslipidemia guidelines have been published by the American College of Cardiology (ACC) and American Heart Association (AHA). The guidelines are a major shift from specific lipid goals to a focus on risk reduction. All pharmacists will need to be familiar with these guidelines in order to provide optimal patient care. Like all ASHP eReports, this is a brief and straightforward presentation of what you need to know about dyslipidemia treatment, the new guidelines, and where you can turn for deeper understanding of the context. Dyslipidemia: Contemporary Evaluation and Management addresses pathophysiology, clinical presentation, diagnosis, and disease classification, general treatment principles, non-pharmacologic...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...
Modern medicine is characterized by a continuous genesis of evidence making it very difficult to t...
Despite significant advances in prevention and treatment, cardiovascular disease continues to be the...
Ischemic heart disease is the leading cause of death worldwide. A disruption to the perfusion and al...
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The ne...
Dyslipidaemia is a common condition managed in general practice. OBJECTIVE: This article reviews the...
Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cau...
AbstractVarious organizations and agencies have issued recommendations for the management of dyslipi...
Dyslipidemia is a major independent risk factor for the development of coronary heart disease, the c...
How to summarize and facilitate the implementation of national and international guidelines in clini...
The first European guidelines for the management of dyslipidaemias produced jointly by the European ...
Dyslipidemia refers to a broad spectrum of various genetic and acquired disorders that affect blood ...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...
Modern medicine is characterized by a continuous genesis of evidence making it very difficult to t...
Despite significant advances in prevention and treatment, cardiovascular disease continues to be the...
Ischemic heart disease is the leading cause of death worldwide. A disruption to the perfusion and al...
Dyslipidemia is a cardiovascular risk factor that is increasing in prevalence in the country. The ne...
Dyslipidaemia is a common condition managed in general practice. OBJECTIVE: This article reviews the...
Dyslipidemia is a major risk factor for cardiovascular events, cardiovascular mortality, and all-cau...
AbstractVarious organizations and agencies have issued recommendations for the management of dyslipi...
Dyslipidemia is a major independent risk factor for the development of coronary heart disease, the c...
How to summarize and facilitate the implementation of national and international guidelines in clini...
The first European guidelines for the management of dyslipidaemias produced jointly by the European ...
Dyslipidemia refers to a broad spectrum of various genetic and acquired disorders that affect blood ...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
The identification of modifiable risk factors for coronary heart disease (CHD) and therapies for the...
Introduction: Cardiovascular diseases (CVDs) are one of the leading causes of morbidity and mortalit...
The key role of dyslipidaemia in determining cardiovascular disease (CVD) has been proved beyond rea...